Pulmonary hypertension (PH) is a multifaceted disorder characterized by the crucial involvement of activated hypoxia-inducible factors (HIFs). Recent investigations have unveiled HIFs' ability to orchestrate a wide array of signaling cascades, encompassing voltage-gated potassium channels, non-selective cation channels (NSCCs), Ca2+/PKC/MAPKs, PI3K/Akt, RhoA/ROCK, Notch, VEGF, and miRNA pathways.
Pulmonary hypertension caused by fibrosing mediastinitis (PH-FM) is a high-risk condition with limited validated tools for prognostic assessment. Although diffusing capacity of the lung for carbon monoxide (DLCO) predicts outcomes in several cardiopulmonary diseases, its prognostic value in PH-FM remains unclear.
Pulmonary hypertension (PH) is a frequent complication of fibrotic interstitial lung diseases (ILDs), but its detection remains challenging due to overlapping clinical features. We aimed to evaluate the discriminatory power of physiological and exercise-based markers that differentiate right heart catheterization (RHC)—confirmed PH from low-probability ILD cases.
Balloon pulmonary angioplasty (BPA) has emerged as a guideline-recommended therapy for surgically inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Lung injury occurs in approximately 6% of BPA sessions and is the leading cause of procedure-related mortality.
Noncommunicable diseases (NCDs) are on the rise in sub-Saharan Africa (SSA), with cardiovascular NCD accounting for most deaths. Pulmonary hypertension (PH) is a highly morbid NCD; however, contemporary prevalence data are lacking.
Pulmonary arterial hypertension (PAH) harboring the heterozygous ring finger protein 213 (RNF213) p.Arg4810Lys variant responds poorly to PAH treatment and has a poor prognosis.
Right heart catheterization (RHC) and echocardiography are integral in the assessment of pulmonary hypertension (PH) and cardiac function for lung transplant (LT) candidates. However, the impact of these metrics on post-LT outcomes remains unclear.
Watch the recording of our PHGPS webinar exploring how patient associations can use the new Data Dashboard to understand global patient insights, support local action, and help shape PHGPS Phase 2.
Pulmonary arterial hypertension (PAH) is a progressive illness that may require therapy with parenteral prostacyclin pathway agents (PPA) (epoprostenol and treprostinil). These parenteral PPA's are continuous ambulatory infusions that require a high level of skill and knowledge to maintain safety and effectiveness.
